Interleukin-1β is associated with depressive episode in major depression but not in bipolar disorder

Journal of Psychiatric Research

Volumn 47, Issue 12, 2013, Pages 2011-2014

  Mota, Rosana ^a   Gazal, Marta ^a   Acosta, Bruna A ^a   de Leon, Pâmela B ^a   Jansen, Karen ^a   Pinheiro, Ricardo T ^a   Souza, Luciano D ^a   Silva, Ricardo A ^a   Oses, Jean P ^a   Quevedo, Luciana ^a   Lara, Diogo R ^b   Ghisleni, Gabriele ^a   Kaster, Manuella P ^a  

^a CATHOLIC UNIVERSITY OF PELOTAS   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Bipolar disorder; Current episode; IL 1 ; Major depression

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1BETA;

ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; DSM-IV; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RISK ASSESSMENT;

BIPOLAR DISORDER; CURRENT EPISODE; IL-1Β; MAJOR DEPRESSION;

ADULT; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; COMMUNITY HEALTH PLANNING; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; PSYCHIATRIC STATUS RATING SCALES; YOUNG ADULT;

EID: 84886088935     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.08.020     Document Type: Article

References (44)

1. Andlin-Sobocki P., Jönsson B., Wittchen H.U. Olesen. Cost of disorders of the brain in Europe. JEur J Neurol 2005, 12:1-27.
2. Angst J. Do many patients with depression suffer from bipolar disorder?. Can J Psychiatry 2006, 51:3-5.
3. Anisman H., Ravindran A.V., Griffiths J., Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999, 4:182-188.
4. Anisman H., Gibb J., Hayley S. Influence of continuous infusion of interleukin-1β on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression. Psychopharmacology 2008, 199:231-244.
5. Benazzi F. Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. JAffect Disord 1997, 43:163-166.
6. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35:804-817.
7. Brambilla F., Monteleone P., Maj M. Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia. JAffect Disord 2004, 78:273-277.
8. Brietzke E., Stertz L., Fernandes B.S., Kauer-Sant'anna M., Mascarenhas M., Escosteguy Vargas A., et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009, 116:214-217.
9. Cardoso de Almeida J.R., Phillips M.L. Distinguishing between unipolar depression and bipolar depression: current and future clinical and neuroimaging perspectives. Biol Psychiatry 2013, 73:111-118.
10. Collins P.Y., Patel V., Joestl S.S., March D., Insel T.R., Daar A.S. Grand challenges in global mental health. Nature 2011, 475:27-30.
11. Constant A., Castera L., Dantzer R., Couzigou P., de Ledinghen V., Demotes-Mainard J., et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. JClin Psychiatry 2005, 66:1050-1057.
12. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
13. Felger J.C., Lotrich F.E. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246:199-229.
14. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. JClin Psychiatry 2009, 70:1078-1090.
15. Haack M. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J.Psychiatr 1999, 33:407-418.
16. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
17. Jansen K., Ores L.C., Cardoso T.A., Lima R.C., Souza L.D., Magalhães P.V., et al. Prevalence of episodes of mania and hypomania and associated comorbidities among young adults. JAffect Disord 2011, 130:328-333.
18. Kaestner F., Hettich M., Peters M., Sibrowski W., Hetzel G., Ponath G., et al. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. JAffect Disord 2005, 87:305-311.
19. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Brietzke E., Vázquez G.H., Vieta E., et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1366-1371.
20. Koo J.W., Duman R.S. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Influence of continuous infusion of interleukin-1beta on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression. Curr Opin Investig Drugs 2009, 10:664-671.
21. Kunz M., Ceresér K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., et al. Gama CS.Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 2011, 33:268-274Leonard B., Stress, depression and the activation of the immune system, World J Biol Psychiatry 1, 2000, 17-25.
22. Leonard B. Stress, depression and the activation of the immune system. World J Biol Psychiatry 2000, 1:17-25.
23. Lewinsohn P.M., Klein D.N., Seeleya J.R. Bipolar disorders during adolescence. Acta Psychiatr Scand 2003, 108:47-50.
24. Lotrich F. Inflammatory cytokines, growth factors, and depression. Curr Pharm Des 2012, 18:5920-5935.
25. Maes M., Song C., Yirmiya R. Targeting IL-1 in depression. Expert Opin Ther Targets 2012, 16:1097-1112.
26. Marques-Deak A.H., Neto F.L., Dominguez W.V., Solis A.C., Kurcgant D., Sato F., et al. Cytokine profiles in women with different subtypes of major depressive disorder. JPsychiatr Res 2005, 41:152-159.
27. Marques A.H., Cizza G., Sternberg E. Brain-immune interactions and implications in psychiatric disorders. Rev Bras Psiquiatr 2007, 29:27-32.
28. McCusker R.H., Kelley K.W. Immune-neural connections: how the immune system's response to infectious agents influences behavior. JExp Biol 2013, 216:84-98.
29. Modabbernia A., Taslimi S., Brietzke E., Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013, 74:15-25.
30. Motovsky B., Pecenak J. Psychopathological characteristics of bipolar and unipolar depression - potential indicators of bipolarity. Psychiatr Danub 2013, 25:34-39.
31. Munkholm K., Braüner J.V., Kessing L.V., Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. JPsychiatr Res 2013, 47:1119-1133.
32. Myint A.M., Schwarz M.J., Steinbusch H.W., Leonard B.E. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 2009, 24:55-68.
33. Owen B.M., Eccleston D., Ferrier I.N., Young A.H. Raised levels of plasma interleukin-1β in major and postviral depression. Acta Psychiatr Scand 2001, 103:226-228.
34. Ortiz-Domínguez A., Hernández M.E., Berlanga C., Gutiérrez-Mora D., Moreno J., Heinze G., et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007, 9:596-602.
35. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001, 49:391-404.
36. Piletz J.E., Halaris A., Iqbal O., Hoppensteadt D., Fareed J., Zhu H., et al. Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry 2009, 10:313-323.
37. Remlinger-Molenda A., Wójciak P., Michalak M., Rybakowski J. Activity of selected cytokines in bipolar patients during manic and depressive episodes. Psychiatr Pol 2012, 46:599-611.
38. Rothermundt M., Arolt V., Peters M., Gutbrodt H., Fenker J., Kersting A., et al. Inflammatory markers in major depression and melancholia. JAffect Disord2001 2001, 63:93-102.
39. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:201-217.
40. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. JClin Psychiatry 1998, 59:22-33.
41. Söderlund J., Olsson S.K., Samuelsson M., Walther-Jallow L., Johansson C., Erhardt S., et al. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. JPsychiatry Neurosci 2011, 36:114-118.
42. Steptoe A. Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women. Psychol Med 2003, 33:667-674.
43. Tsai S.Y., Chung K.H., Wu J.Y., Kuo C.J., Lee H.C., Huang S.H. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 2012, 136:110-116.
44. van de Veerdonk F.L., Netea M.G. New Insights in the Immunobiology of IL-1 Family Members. Front Immunol 2013, 8:4-167.